# A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

> **NCT02696798** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 316 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02696798
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-12
- **Primary completion:** 2018-05-18
- **Final completion:** 2019-05-03
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02696798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02696798, "A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02696798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*